Abstract
To the Editor, Javaugue et al. recently showed that over 90% of IgG3 proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) cases lack a monoclonal etiology, using their highly sensitive immunoglobulin repertoire sequencing (RACE-RepSeq) of bone marrow (BM) RNA. Many instead likely reflect oligoclonal or polyclonal immune responses to viral or bacterial antigens [1]. We report a young female who developed severe crescentic, oliguric, dialysis-requiring acute kidney injury with IgG3 PGNMID 2 weeks after a flu-like illness, successfully treated with rituximab. A 40-year-old female with no significant medical history except for obesity and preeclampsia (2009 and 2023), who was noted to have elevated blood pressure (150/95 mmHg), hematuria, and proteinuria on urine analysis during an emergency room visit in August 2024, during a flu-like illness (fever 102.9 °F), but no further workup was pursued. Serum creatinine (S. Cr) was 0.9 mg/dl (79.6 µmol/l), and blood pressure was normalized on follow-up home measurements. She developed another flu-like illness (fever 101.0 °F; COVID-19, influenza A and B were negative) in March 2025. Two weeks later, the patient presented to the emergency room with new onset elevated blood pressure (213/113 mmHg) and acute kidney injury, with S. Cr 4.1 mg/dl (362.4 µmol/l), rising to 13 mg/dl (1149.2 µmol/l) within 10 days, along with oliguria (nadir urine output 200 ml/day). Kidney biopsy findings on light microscopy showed 76% cellular crescents (19 of 25 glomeruli), with virtually all glomeruli demonstrating a membranoproliferative pattern (endocapillary hypercellularity and capillary wall double contouring), 20% interstitial fibrosis, and focal acute tubular injury, with minimal inflammatory cells in the interstitium. Immunofluorescence was positive for IgG (3+), C3 (3+), C1q (3+), kappa light chain (trace), and lambda light chain (4+) with IgG3 subclass (3–4+), and electron microscopy showed mesangial and subendothelial electron-dense deposits (Supplementary Fig. S1) with overall findings consistent with PGNMID. Despite thorough testing, no pathological clone was found (Fig. 1A). She began hemodialysis, high-dose steroids, and received rituximab 1 g before discharge to outpatient dialysis. Two months after rituximab, urine output increased to 2600 ml/day, combined urea and creatinine clearance rose to 15 ml/min, and dialysis was discontinued. Another dose of rituximab 1 g was given at this time, and by 6 months, S. Cr improved to 1.98 mg/dl, with random urine protein/creatinine of 0.5 and urine microscopy showing 3 red blood cells/hpf. Peripheral blood CD20 cell count remained at 0 cells/µl, measured 2 days after the first dose, prior to discharge, and monthly thereafter up to 8 months from the first dose of rituximab (Fig. 1B). (A) Workup at the time of kidney biopsy. (B) Clinical course. FLC, free light chain; κ, kappa; λ, lambda; SPEP, serum protein electrophoresis; SIF, serum immunofixation; MALDI-TOF MS, matrix-assisted laser desorption ionization time-of-flight mass spectrometry; CT scan, computerized tomography scan. a. Number of events acquired: 4544 236; lower limit of detection 0.0011%; antigens examined: cKappa, cLambda, CD19, CD27, CD38, CD45, CD56, CD81, CD117, cVS38c; overall plasma cell kappa:lambda ratio: ∼1:1. Note: high-sensitivity flow cytometry achieves ∼10⁻⁵ detection (1 clonal plasma cell per 100 000 cells). We previously reported pregnancy-associated PGNMID [3]. However, subsequent normalization of blood pressure and kidney function makes pregnancy an unlikely primary cause of the current presentation in this case. Instead, a flu-like illness raises the possibility of triggering an oligoclonal or polyclonal response secondary to small B-cell clone stimulation from viral antigen, leading to infection-associated PGNMID, which may or may not represent a “second-hit” phenomenon. This is consistent with the findings in the multicenter series reported by Javaugue et al., in which infections within 1 year before diagnosis were observed in 7/42 patients (17%), all with IgG3 PGNMID, and BM examination showed overrepresentation of the IgG1 isotype in immunoglobulin repertoires compared to controls, suggesting an adaptive immune response against viral or bacterial protein antigens [1]. Although steroids may temporarily help control inflammation in cases of PGNMID, steroid monotherapy can worsen proteinuria and yield an incomplete response, as noted in previous cases [3,4], and clone-directed therapy remains the treatment standard [5]. However, bridging with steroids may be helpful, especially during rapidly declining renal function, until clone-directed therapy is initiated and its effects are evident. Among non-IgM PGNMID patients without a detectable clone, previous data indicate that some respond only to anti-CD20 B-cell-directed therapy, whereas others respond only to anti-CD38 plasma cell-directed therapy [2–4]. Yet, as of 2025, no data exist on how to prioritize these therapies [4,5]. We previously suggested that age at diagnosis may be helpful [3]. Here, we propose that infection-triggered PGNMID may respond well to anti-CD20 B-cell-directed therapy; however, the risk of relapse remains unknown, given the limited follow-up in our case. Further studies are needed to identify factors that can guide therapy prioritization. Additionally, clinical trials of daratumumab for PGNMID should consider reporting pre-enrollment infection history and offer nonresponders an option for anti-CD20 B-cell-directed therapy. Informed consent was obtained from the patients described in this report. All authors declare that there is no conflict of interest.